NHS to trial innovative cancer blood test

The NHS is trialling an innovative new blood test that may be able to detect more than 50 types of cancer. The Galleri blood test, developed by a company called GRAIL, will be piloted with 165,000 patients. Prior research on patients with signs of cancer has already found that the test, which checks for molecular […]

read more

Delay in cancer diagnosis during COVID-19 – what next?

This article in The Lancet describes the impact of the COVID-19 pandemic on the two-week wait referral for cancer diagnosis in the UK from the results of two modelling studies looking at up to 20 different cancers. The article concludes that patients whose symptoms indicate cancer have been disadvantaged, and some patients will die as […]

read more

Challenges of early detection of renal cell carcinoma

The incidence of kidney cancer in the UK has risen by 47% over the past decade, with 12 000 new cases in 2015. Diagnosing patients with kidney cancer can be challenging. The majority of kidney cancers are renal cell carcinomas (RCCs), which make up about 85% of kidney cancers. Signs and symptoms of RCC are […]

read more

New test for the early detection of kidney cancer

Renal cell carcinoma (RCC) has poor survival because it does not show any symptoms at an early stage when it can be treated successfully. Researchers have developed a paper-based ‘plasmonic biosensor’ test using the detection of perilipin-2 (PLIN-2), a protein involved in the mobilisation of fat in the body, in urine to facilitate the early […]

read more

NHS Rapid Diagnostic Centres – vision and implementation specification

The NHS Cancer Programme has published the Vision and 2019/20 Implementation Specification for Rapid Diagnostic Centres, a key element of the NHS Long Term Plan for cancer. This document outlines the vision and approach for how Rapid Diagnostic Centres will develop and support the transformation of cancer diagnosis services over time. It also describes how […]

read more

Liquid biopsy to detect cancer early

A new liquid biopsy test developed by scientists in the US, Denmark and the Netherlands and published in the journal Nature correctly detected the presence of cancer in the majority of cases, and identified the tissue with the primary tumour approximately 75% of the time. The test is a modified liquid biopsy test. A liquid […]

read more

Potential kidney cancer test in development

A Swedish biotechnology company, Elypta, has recently been awarded an EU grant for the development of a new test for the diagnosis of renal cell carcinoma (RCC). The grant of £2.4m will be used to run a clinical trial to validate Elypta’s technology as a tool for monitoring patients who have been treated for RCC […]

read more

Breath test for cancer enters clinical trials

Cancer Research UK are pioneering a potential breath test for cancer. A clinical trial, being led by Professor Rebecca Fitzgerald, is about to start at the MRC Cancer Unit at the University of Cambridge. The trial is looking at ways to bring this potential cancer test into the clinic. “The PAN trial is seeing if you […]

read more

Potential of microRNAs as biomarkers for renal cell carcinoma

A recent review of the knowledge about the potential clinical applications of microRNAs (miRNAs) has been published in the Central European Journal of Urology. Specific biomarkers for the early detection and monitoring of renal cell carcinoma (RCC) would enable early diagnosis of the disease. A non-invasive and sensitive biomarker would also be extremely useful for […]

read more

Kidney cancer may begin to develop in childhood

Scientists working on a Cancer Research UK funded study have discovered that the development of kidney cancer follows distinct paths, which can begin in childhood. These evolutionary paths enable scientists to detect whether a tumour will be aggressive and spread. “We could use these rules to help choose the best treatments, and potentially to diagnose some […]

read more
Showing 1 to 10 of 17 results
  TOP